Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (HK:2185) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shanghai Bio-heart Biological Technology Co., Ltd. announces that its subsidiary, AngioCare, has reached an agreement with Terumo to waive exclusive distribution rights for its RDN products in the Greater China region, opening opportunities for new collaborations and expanded market reach. This strategic decision aims to leverage internal resources and enhance future commercialization efforts without adversely affecting the company’s operations.
For further insights into HK:2185 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue